1,280 words · Editorial
What "Not FDA-Approved" Actually Means When You're Buying Compounded GLP-1s
The phrase gets repeated so often it stops landing. Here are the concrete consequences — including the two that flip the price comparison entirely.
Published
Key takeaways
- "Not FDA-approved" means the specific formulation never went through the review that tests safety, purity, potency, and consistency — not that the molecule is unknown.
- Compounded preparations vary by pharmacy in concentration and labeling, which is why dosing errors in this category trace to units-versus-milligrams confusion.
- The compounded cash price is permanent and unappealable — there is no insurance appeal, no formulary exception, and no manufacturer copay card behind it.
- Adverse events with compounded products have no manufacturer pharmacovigilance system behind them the way approved products do.
- Compounded GLP-1s are neither a scam nor equivalent to approved products — they are a different category with a different risk and financial structure.
Every article about compounded semaglutide and tirzepatide includes the sentence "compounded drugs are not FDA-approved." It appears so reliably that it's become background noise — a disclaimer readers skim past on the way to the price.
So let's make it concrete. Not as a warning, but as a list of things that are actually different, including the two that most affect what you'll pay over a year.
First, what compounding is
Compounding is a pharmacy preparing a medication for a patient. It's a legitimate, long-standing practice with real clinical uses — a patient who needs a formulation without a particular dye, or a dose that isn't manufactured.
What it is not is a generic. A generic drug goes through an FDA approval process demonstrating it's equivalent to the brand. A compounded preparation doesn't. They're different categories, and conflating them is the root of most confusion here.
One terminology point worth being firm about: there is no such thing as "compounded Ozempic," "compounded Zepbound," or "generic Ozempic." Those are branded products; the compounded thing is compounded semaglutide or compounded tirzepatide — a different, unapproved product containing the same active ingredient. A seller using the branded phrasing is either confused about what they're selling or hoping you are. Treat it as a signal.
The concrete differences
Strength is not FDA-verified. With an approved product, the amount of drug in the dose has been established through the approval process. With a compounded preparation, it depends entirely on the pharmacy that made it.
The finished product wasn't studied. The clinical trials you've read about tested the approved products. The compounded version is a different preparation that was not itself in those trials — so the efficacy and safety data don't transfer cleanly to it, even though the molecule is the same.
Labeling and instructions vary. Approved products ship with standardized Instructions for Use. Compounded preparations vary by pharmacy, which matters more than it sounds — dosing errors in this category have frequently traced back to confusion between units and milligrams, especially with vial-and-syringe presentations rather than pens.
Salt forms have been a documented concern. The FDA has flagged compounded products using salt forms — semaglutide sodium, semaglutide acetate — which are not the same as the base semaglutide in the approved products. If you're considering compounded, this is a question to ask explicitly and get answered in writing.
Recall and safety-reporting infrastructure is limited. Approved products sit inside an established system for identifying and communicating problems. That infrastructure is thinner for compounded preparations.
The two consequences that flip the price comparison
Here's what almost never gets said, and it's the part with the largest financial impact.
Insurance essentially never covers compounded drugs
That means the cash price is the entire price, permanently. There is no copay to fall back on. There is no manufacturer assistance program behind it. And if the program raises its prices, you have no recourse.
An approved product behaves completely differently. If it's covered, you pay a copay — often a fraction of any cash price. If it's denied, you can appeal, and denials are frequently overturned because they're often documentation problems rather than eligibility verdicts.
So the real comparison isn't the one people run
The comparison people make is "$200 a month versus $500 a month."
The comparison that actually matters is:
"$200 a month forever, guaranteed, with no route to change it" versus "possibly a copay, possibly $500, with an appeal process and manufacturer programs behind it."
Those are very different propositions, and the second one is frequently better even when its headline number is higher.
Before choosing the compounded path on price, find out what your plan would actually charge for the approved product. That's one phone call, and it's the highest-value call in this entire decision.
The gap has also narrowed on the headline number
Two things happened that make the raw price comparison closer than the reputation suggests.
Compounded prices are usually quoted for the starting dose, medication only. Real all-in cost adds the consultation or membership fee, lab work if required, higher pricing at maintenance strengths, and shipping. Compounded tirzepatide is worse for this than semaglutide, because it has more dose steps and compounded pricing is normally tiered by strength — so a starting-dose quote can be a long way from your cost six months later.
The manufacturers launched their own cash programs. As of mid-2026: Zepbound self-pay starts at $299/month at the 2.5 mg starting dose and $399 at 5 mg. Wegovy's cash program runs about $349/month at maintenance with a $199 introductory price. The oral Wegovy pill starts around $149/month. Those are FDA-approved products at manufacturer prices — a very different landscape from 2023.
Also: the shortages ended
The widespread compounding of these drugs was tied to FDA shortage declarations. Those shortages were resolved — tirzepatide in December 2024, semaglutide in February 2025 — and the enforcement conditions that permitted large-scale compounding lapsed through 2025.
So the market changed. Compounding for a documented individual clinical need can still be legitimate; large-scale production of copies of commercially available approved drugs is a different matter. If a site is still selling cheaply with no real clinical evaluation, that's worth noticing.
If you still choose compounded, ask these six questions
There are real reasons someone ends up here, and cost is a legitimate one. If you do, these reduce your risk — and a program that won't answer them in writing has told you something useful:
- Which pharmacy dispenses this, and where is it licensed? You should be able to find out. A program that won't say is asking for trust it hasn't earned.
- Is this base semaglutide/tirzepatide, not a salt form? Get the answer in writing.
- What are the dosing instructions, in both units and milligrams? Vagueness here is a reason to stop, not a reason to ask again.
- What do I pay all-in at my maintenance dose? Not the starting-dose headline. Ask for the full price ladder across every strength.
- What's the refund policy if I stop? Discontinuation during titration is common, mostly from gastrointestinal side effects. A six-month prepaid plan transfers that risk from the program to you.
- Who do I contact clinically if something goes wrong? There should be a named clinician, not a support inbox.
The honest summary
Compounded GLP-1s aren't a scam, and they aren't equivalent to approved products. They're a different category with a different risk profile and — critically — a different financial structure, where the cash price is permanent and unappealable.
That last point is the one to weigh hardest, because it's the one that plays out over years rather than months.
I maintain the detailed cost breakdowns and the honest side-by-side comparisons here: compounded semaglutide cost, compounded tirzepatide cost, and compounded semaglutide vs Ozempic.
Sources
- FDA — Compounding and the FDA: questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- FDA Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/
- NovoCare — Wegovy and Ozempic self-pay programs: https://www.novocare.com
- Zepbound coverage and savings — Eli Lilly: https://zepbound.lilly.com/coverage-savings
Prices and regulatory status checked July 2026 and change frequently — verify current figures directly.
Educational information, not medical advice. Whether any of these products is appropriate for you is a decision for a licensed clinician.
Common questions about What "Not FDA-Approved" Actually Means When You're Buying Compounded GLP-1s
What does "not FDA-approved" mean for compounded semaglutide?
It means the specific compounded formulation has not been through FDA review, so nobody has verified its purity, potency, or batch-to-batch consistency the way they do for an approved product. The underlying molecule is well studied; the particular preparation from a particular pharmacy is not.
Can I appeal the price of compounded GLP-1 to my insurance?
No. Because the product is not FDA-approved, there is no formulary to add it to, no prior authorization to win, and no manufacturer copay card. Whatever the compounding pharmacy charges is the price, permanently — which is the part that flips the long-run comparison against brand products whose cost can be appealed or offset.
Is compounded tirzepatide safe?
It carries a different risk profile than the approved product rather than a simple yes or no. The formulation has not been FDA-reviewed for purity and consistency, it usually ships as a vial and syringe that reintroduces dosing-conversion risk, and adverse events lack the manufacturer surveillance an approved product has. Those are the specific trade-offs to weigh with a prescriber.